[go: up one dir, main page]

CL2016001570A1 - Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas - Google Patents

Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Info

Publication number
CL2016001570A1
CL2016001570A1 CL2016001570A CL2016001570A CL2016001570A1 CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1 CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1
Authority
CL
Chile
Prior art keywords
activity
vortioxetine
treatment
depressive disorder
receptor antagonist
Prior art date
Application number
CL2016001570A
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2016001570A1 publication Critical patent/CL2016001570A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K PARA USARSE EN EL TRATAMIENTO DE UN TRASTORNO DEPRESIVO CON CARACTERISTICAS MENANCOLICAS; COMBINACION DE UN ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K Y VORTIOXETINA PARA EL MISMO USO; Y COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K Y VORTIOXETINA.
CL2016001570A 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas CL2016001570A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16

Publications (1)

Publication Number Publication Date
CL2016001570A1 true CL2016001570A1 (es) 2016-12-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001570A CL2016001570A1 (es) 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Country Status (14)

Country Link
US (1) US10376506B2 (es)
EP (1) EP3082815B1 (es)
JP (1) JP6448645B2 (es)
KR (1) KR20160093025A (es)
CN (1) CN105828821B (es)
AU (1) AU2014368548B2 (es)
CA (1) CA2933733A1 (es)
CL (1) CL2016001570A1 (es)
ES (1) ES2694352T3 (es)
IL (1) IL246253A0 (es)
MX (1) MX368870B (es)
RU (1) RU2679661C1 (es)
SG (1) SG11201604944PA (es)
WO (1) WO2015091833A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7549576B2 (ja) 2018-11-06 2024-09-11 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイドアンタゴニストを送達するための組成物及び方法
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2025197843A1 (ja) * 2024-03-18 2025-09-25 学校法人東京理科大学 アンヘドニアの治療又は予防用医薬組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007064586A1 (en) * 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
ES2337622T3 (es) * 2006-04-04 2010-04-27 Emodys Gmbh Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
ATE540941T1 (de) 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2010136039A1 (en) 2009-05-25 2010-12-02 H. Lundbeck A/S Preparation of nalmefene hydrochloride from naltrexone
WO2011020030A2 (en) * 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
JP6246589B2 (ja) 2010-11-05 2017-12-13 ハー・ルンドベック・アクチエゼルスカベット ナルトレキソンの製造方法
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
WO2014170351A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Also Published As

Publication number Publication date
CA2933733A1 (en) 2015-06-25
SG11201604944PA (en) 2016-07-28
MX368870B (es) 2019-10-21
RU2016123972A (ru) 2018-01-25
EP3082815A1 (en) 2016-10-26
ES2694352T3 (es) 2018-12-20
MX2016007947A (es) 2016-09-09
EP3082815B1 (en) 2018-10-03
CN105828821B (zh) 2019-04-09
CN105828821A (zh) 2016-08-03
JP6448645B2 (ja) 2019-01-09
KR20160093025A (ko) 2016-08-05
WO2015091833A1 (en) 2015-06-25
IL246253A0 (en) 2016-07-31
RU2679661C1 (ru) 2019-02-12
AU2014368548B2 (en) 2019-09-19
JP2016540030A (ja) 2016-12-22
AU2014368548A1 (en) 2016-06-30
US10376506B2 (en) 2019-08-13
US20160310488A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PL2956471T3 (pl) Kompozycja inhibitora il-1beta i jej zastosowanie
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral
UY34829A (es) Nueva dosificación y formulación
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.